Kim N. Chi
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cancer Research top 0.1%
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
-
- Prostate Cancer Treatment and Research 169
- Prostate Cancer Diagnosis and Treatment 24
-
- Cancer Genomics and Diagnostics 25
- Cancer, Lipids, and Metabolism 14
- Co-authors
- Karim S. Fizazi (28 shared papers)Ronald de Wit (3 shared papers)Johann Sebastian De Bono (26 shared papers)Fred Saad (36 shared papers)Ian F. Tannock (4 shared papers)Mark Andrew Rosenthal (3 shared papers)Mario A. Eisenberger (3 shared papers)Stéphane Marie. Oudard (4 shared papers)
- Journals
- European Urology (24 papers)Journal of Clinical Oncology (22 papers)Clinical Cancer Research (18 papers)The Journal of Urology (14 papers)The Lancet Oncology (11 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Kim N. Chi
243 papers receiving 39.0k citations
Kim N. Chi's Hit Papers
Peers
Comparison fields: 5 of 152
- Pulmonary and Respiratory Medicine 27.7k
- Cancer Research 8.2k
- Oncology 8.4k
- Radiology, Nuclear Medicine and Imaging 5.4k
- Endocrinology, Diabetes and Metabolism 2.4k
Countries citing papers authored by Kim N. Chi
This map shows the geographic impact of Kim N. Chi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim N. Chi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim N. Chi more than expected).
Fields of papers citing papers by Kim N. Chi
This network shows the impact of papers produced by Kim N. Chi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim N. Chi. The network helps show where Kim N. Chi may publish in the future.
Co-authors
The 25 scholars most cited alongside Kim N. Chi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 258 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Hit paper breakdown → | 2004 | 4744 |
| 2 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Hit paper breakdown → | 2012 | 3725 |
| 3 | Abiraterone and Increased Survival in Metastatic Prostate Cancer Hit paper breakdown → | 2011 | 3637 |
| 4 | Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2021 | 1895 |
| 5 | Olaparib for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 1753 |
| 6 | Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Hit paper breakdown → | 2009 | 1737 |
| 7 | Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Hit paper breakdown → | 2017 | 1714 |
| 8 | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 Hit paper breakdown → | 2016 | 1297 |
| 9 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Hit paper breakdown → | 2019 | 1169 |
| 10 | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Hit paper breakdown → | 2012 | 1141 |
| 11 | Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer Hit paper breakdown → | 2019 | 1127 |
| 12 | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2019 | 618 |
| 13 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 603 |
| 14 | Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study Hit paper breakdown → | 2018 | 587 |
| 15 | Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer Hit paper breakdown → | 2018 | 585 |
| 16 | Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer Hit paper breakdown → | 2018 | 434 |
| 17 | Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer Hit paper breakdown → | 2015 | 413 |
| 18 | Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer Hit paper breakdown → | 2016 | 363 |
| 19 | Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study Hit paper breakdown → | 2021 | 358 |
| 20 | 2017 | 342 |
About Kim N. Chi
Kim N. Chi is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 258 papers that have together received 39.7k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (169 papers), Cancer Genomics and Diagnostics (25 papers), Prostate Cancer Diagnosis and Treatment (24 papers), Radiopharmaceutical Chemistry and Applications (21 papers), Cancer, Lipids, and Metabolism (14 papers), Bladder and Urothelial Cancer Treatments (12 papers), Clusterin in disease pathology (12 papers) and PARP inhibition in cancer therapy (12 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (27.7k citations), Cancer Research (8.2k citations), Oncology (8.4k citations), Radiology, Nuclear Medicine and Imaging (5.4k citations) and Endocrinology, Diabetes and Metabolism (2.4k citations). Kim N. Chi has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Karim S. Fizazi, Ronald de Wit, Johann Sebastian De Bono, Fred Saad, Ian F. Tannock, Mark Andrew Rosenthal, Mario A. Eisenberger, Stéphane Marie. Oudard, Jozsef Horti and William R. Berry. Their work appears in journals such as European Urology, Journal of Clinical Oncology, Clinical Cancer Research, The Journal of Urology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.